China is expanding a volume-based purchasing scheme for drugs and the second round of the “4+7” centralized drug procurement program for major cities, announced right before the lunar new year in late January, has had a ripple effect on pharma companies across the country.
Out of a total of 33 drugs selected by the National Medical Insurance Administration, 32 have secured winning bids, showing...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
